Capecitabin

Capecitabine is used for the treatment of colorectal and breast cancers. It is contraindicated in patients with known hypersensitivity to capecitabine or any of its components or to 5-fluorouracil and in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency. The use of capecitabine is restricted in patients with severe renal impairment. The drag can induce diarrhea, sometimes severe. Other side effects include anemia, hand-foot syndrome, hyperbilirubinemia, nausea, stomatitis, pyrexia, edema, constipation, dyspnea, neutropenia, back pain, and headache. Cardiotoxicity has been observed with capecitabine. A clinically important drag interaction between capecitabine and warfarin has been demonstrated. Care should be exercised when the drag is co-administered with CYP2X9 substrates. 

C27H42FN3O10 174667-24-4) see Capecitabine 5 -deoxy-5-fluoro-A-[(pentyloxy)carbonyl]cytidine 2, 3 -diacetate... 

C5HiyNSi2, 999-97-3) see Aciclovir Capecitabine Ganciclovir Mecillinam Tegafur Trifluridine... 

Tsukamoto Y, Kato Y, Ura M, Horii I, Ishitsuka H, Kusuhara H, Sugiyama Y. A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans the mechanism for tumor-selective accumulation of 5-FU. Pharm Res 2001 Aug 18(8) 1190-202. 

Capedtabine is the prodrug of 5-FU and comes as oral tablets that are administered with food twice a day. Capedtabine has shown to be active in tumors of the colon, rectum, and breast. The toxicity profile of capecitabine is similar to that of 5-FU and includes diarrhea, mucositis, palmar-plantar erythrodysesthesia,... 

Capecitabine Capecitabine 2000-2500 mg/m2 per day orally, divided twice daily for 14 days Repeat cycles every 21 days1 - Liposomal doxorubicin Liposomal doxorubicin 30-50 mg/m2 IV over 90 minutes Repeat cycles every 21-28 days5... 

Docetaxel + capecitabine Docetaxel 75 mg/m2 IV over 1 hour, day 1 Capecitabine 2000-2500 mg/m2 per day orally divided twice daily for 14 days Repeat cycles every 21 days Epirubicin + docetaxel" Epirubicin 70-90 mg/m2 IV bolus Followed by Docetaxel 70-90 mg/m2 IV over 1 hour Repeat cycles every 21 daysv Doxorubicin + docetaxel" Doxorubicin 50 mg/m2 IV bolus, day 1 Followed by Docetaxel 75 mg/m2 IV over 1 hour, day 1 Repeat cycles every 21 days"... 

Antimetabolites Capecitabine Diarrhea, palmar-plantar erythrodysesthesias (hand-foot syndrome) Myelosuppression, stomatitis, nausea, vomiting... 

Capecitabine 1250 mg/m2 twice a day orally for 14 days Repeat every 3 weeks... 

CAPIRI Capecitabine 1 000 mg/m2 twice a day for 14 days Irinotecan 100 mg/m2 IV days 1 and 8 Repeat every 22 days... 

CAPOX Capecitabine + Oxaliplatin given as oral therapy and IV boluses... 

Capecitabine is an oral prodrug of 5-FU that also is effective in the adjuvant setting and is being evaluated as a replacement for 5-FU for patient convenience and safety reasons. Data suggest that capecitabine is at least equivalent to 5-FU and leucovorin in efficacy and is better tolerated by patients.24 Consequently, most practitioners feel that capecitabine is an acceptable alternative to IV 5-FU plus leucovorin. However, the role of capecitabine with additional chemotherapy agents such as oxaliplatin requires further study... 

Capecitabine or 5-fluorouracil plus leucovorin with or without bevacizumab... 

Capecitabine (Xeloda ) Orally active prodrug of 5-fluorouracil. Once activated, the mechanism of action is the same. Similar to continuous infusion 5-fluorouracil... 

The dose of capecitabine begins at 1250 mg/m2 twice a day when used by itself lower doses are used often when it is given in combination with irinotecan or oxaliplatin or in patients with renal insufficiency. The dose should be taken on a full stomach with breakfast and dinner. Capecitabine administered with warfarin can result in significant increases in the patient s INR and requires close monitoring to prevent bleeding. The convenience of oral administration and an improvement in toxicity make capecitabine a useful alternative to IV 5-FU both by itself and incorporated into other regimens used in colon cancer. 

---